anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Experimental group: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
Itch is a common symptom of dermatologic diseases associated with significant impairment of health-related quality of life (QoL). This study reveals disparities in itch symptom experience and itch impact on QoL. A retrospective study of patient-reported outcome measure (PRO) data (ItchyQoL, Itch NRS, Pain Interference, Anxiety) for 387 outpatient dermatology visits to characterize the impact of itch on patients' QoL and itch symptom experience based on skin color in patients with dermatologic disease. Most patients were Caucasian females (67%) with mean age of 48 years. Correlative analyses showed mild itch associated with emotional impacts on QoL (p < 0.01), while severe itch associated with functional and emotional impacts on QoL (p < 0.01). African American (AA) patients reported more "severe-range" answers for 15 (68%) ItchyQoL items and had higher ItchyQoL mean scores (p = 0.001). ItchyQoL demonstrated an emotional impact on QoL by mild itch, but a functional and emotional impact on QoL by severe itch. Further, AAs suffered from greater itch-related impairment in QoL than Caucasian patients, especially due to scarring and sleeplessness.
Crystallized derivatives of germinal gland hormones are prepared by forming addition compounds of the hormones with quinoline.  Pure hormones may be obtained by decomposing the compounds with dilute acids.  According to an example follicle hormone of the formula C18H22O2 is heated with an equal weight of quinoline and the crystal paste which forms on cooling is pressed out on porous tile.  The molecular compound may be recrystallized from ether or pure alcohol. An ether solution may be extracted with dilute hydrochloric acid to remove the quinoline leaving the pure hormone in solution.ALSO:Crystallized derivatives of germinal gland hormones are prepared by combining the hormones with quinoline.  Pure hormones may be obtained by decomposing the compounds with dilute acids. According to an example follicle hormone of the formula C18H22O2 is heated with an equal weight of quinoline.  On cooling the whole solidifies to a crystal paste which is pressed out on porous tile.  The molecular compound can be recrystallized from ether or pure alcohol.  An ether solution of the compound may be extracted with dilute hydrochloric acid to remove the quinoline leaving the pure hormone in solution.
Morphine Sulfate Injection is an opioid agonist, available as 1 mg/mL (in a 30 mL vial) for use with a compatible Alaris® infusion device. The chemical name is 7, 8-didehydro-4, 5α-epoxy-17-methylmorphinan-3, 6α-diol sulfate (2:1) (salt), pentahydrate. Its molecular formula is (C17H19NO3)2•H2SO4•5H2O, and it has the following chemical structure.

Morphine sulfate USP is an odorless, white crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol:water partition coefficient of morphine is 1.42 at physiologic pH and the pKa is 7.9 for the tertiary nitrogen (the majority is ionized at pH 7.4).

Preservative-free Morphine Sulfate Injection, is a sterile, nonpyrogenic solution of morphine sulfate in water for injection, to be administered by the intravenous route with a compatible Alaris® infusion device.

Preservative-free Morphine Sulfate Injection contains morphine sulfate, (pentahydrate) 1 mg and sodium chloride, USP, 9 mg in water for injection, USP. May contain sodium hydroxide and/or hydrochloric acid for pH adjustments.

The pH range for preservative-free Morphine Sulfate Injection is 2.5 to 6.5.

Morphine Sulfate Injection, contains no antioxidant, bacteriostatic or antimicrobial agent, and is intended only as a single-dose unit, to provide analgesia via the intravenous route, using a compatible Alaris® infusion device.
<P>PROBLEM TO BE SOLVED: To provide a poly(β-amino ester) which is prepared by conjugate adding a bis(secondary amine) or a primary amine to a bis(acrylic acid ester).  <P>SOLUTION: The poly(β-amino ester) is prepared by conjugate adding the bis(secondary amine) or the primary amine to the bis(acrylic acid ester). These tertiary-amine-containing polymers are preferably biodegradable and biocompatible, and also usable in various drug delivery systems. The polymers are especially suitable for delivery of a polynucleotide due to poly(amine) properties of the polymers. Nano particles containing a polymer/polynucleotide complex are prepared. Then, other agents to be delivered can be encapsulated using the polymer. These are especially useful in delivery of unstable agents if taking capability for bufferizing these surrounding pH's into consideration.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Early detection of the risk of sarcopenia at younger ages is crucial for implementing preventive strategies, fostering healthy muscle development, and minimizing the negative impact of sarcopenia on health and aging. In this study, we propose a novel sarcopenia risk detection technique that combines surface electromyography (sEMG) signals and empirical mode decomposition (EMD) with machine learning algorithms. First, we recorded and preprocessed sEMG data from both healthy and at-risk individuals during various physical activities, including normal walking, fast walking, performing a standard squat, and performing a wide squat. Next, electromyography (EMG) features were extracted from a normalized EMG and its intrinsic mode functions (IMFs) were obtained through EMD. Subsequently, a minimum redundancy maximum relevance (mRMR) feature selection method was employed to identify the most influential subset of features. Finally, the performances of state-of-the-art machine learning (ML) classifiers were evaluated using a leave-one-subject-out cross-validation technique, and the effectiveness of the classifiers for sarcopenia risk classification was assessed through various performance metrics. The proposed method shows a high accuracy, with accuracy rates of 0.88 for normal walking, 0.89 for fast walking, 0.81 for a standard squat, and 0.80 for a wide squat, providing reliable identification of sarcopenia risk during physical activities. Beyond early sarcopenia risk detection, this sEMG-EMD-ML system offers practical values for assessing muscle function, muscle health monitoring, and managing muscle quality for an improved daily life and well-being.
The composition is characterised by containing     a) orotic acid or a salt of orotic acid and   b) inosine preferably nicotinamide orotate, choline orotate, thiamine disulphide orotate, Mg orotate or K orotate, and optionally vitamin B12, folic acid and vitamin A (water-soluble form). Particular embodiments contain an ointment base known per se, or skin ointment base and are in gel form or in water-soluble form. It emerges, surprisingly, that the composition according to the invention on topical use represents a rapid, well-tolerated, easily obtainable composition which has broad efficacy and few or no side effects for the treatment of skin disorders, e.g. chr. dermatitis (= eczema vulgare), toxic dermatitis and damage (erosions, lesions) of the skin in the perianal region of babies, superficial injuries of the skin, neurodermatitis, disorders of the mucous membranes (inflammations of the airways (rhinitis, bronchitis, laryngitis, sinusitis, tracheitis), balanitis, chr. gingivitis (periodontosis), aphthous stomatitis, chr. conjunctivitis, disorders of nail growth, cutaneous burns, hair loss, chr. gastritis, chr. vaginitis, fissures and rhagades with cosmetic action. The abovementioned disorders are otherwise mainly resistant to current therapy. The results of the clinical investigations indicate that these disorders comprise a deficiency of purine and pyrimidine nucleotides or their precursors.
The invention relates to a pharmaceutical composition and a dosage form for treating incontinence with oxybutynin and a second drug.  The aforementioned drug substance can be any drug that is used to treat incontinence.  The dosage form can include, independently, therapeutic or subtherapeutic quantities of oxybutynin and the second drug, depending on the administration method, the dosage form employed and the second drug used.  Particular configurations of said composition include a dosage form that releases oxybutynin and the second drug in a controlled manner in order to maintain effective therapeutic levels of oxybutynin and/or the second drug in a mammal for an extended period of time.  According to the invention, an osmotic device is provided which comprises a double-layer core.  The aforementioned osmotic device provides dual controlled release of both drugs from the core.  The invention also relates to a method of treating urinary incontinence (stress or emergency) with a pharmaceutical composition and a dosage form.  The combination of the oxybutynin and the second drug provides an improved general clinical benefit in relation to all other agents which are administered alone, with approximately the same dose.
Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
The present invention provides a covalent organic framework for the diagnostic combination of hypoxia-activated therapy and self-accelerated drug release to coordinate cancer immunotherapy, incorporating highly efficient AIE luminophores and DACs into a hypoxia-responsive COF. The COF is constructed by an azo-phenyl group-containing monomer, can be degraded in the presence of azo reductase under the anoxic condition, and promotes the ordered release of a chemotherapeutic medicine DAC. AIEgen induced PDT effects help to intensify hypoxia and thereby accelerate the progress of drug release. In addition, azo-based COFs exhibit the ability to quench AIEgen fluorescence by the PET effect. Both fluorescence and PDT properties undergo significant enhancement after hypoxia triggered COF degradation. The nano-agent can sensitively depict tumor sites in vivo by in situ activatable fluorescent markers. Once in tumor tissue, such nanoplatforms exhibit the potential to induce potent PDT effects and efficient induction of tumor cell apoptosis. The PDT effect interacts synergistically with the released DAC drug to further enhance apoptosis.
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: invention proposes irrigative composition "Gidroelastic" for an intraocular application containing sodium chloride and water and, additionally, sodium buffer salts and water-soluble polymers taken in the following ratio of components, wt.-%: sodium chloride, 0.138-0.164 M; sodium buffer salts, 0.001-0.030 M; water-soluble polymers, 0.020-20.0; water, the balance, with pH value from 6.8 to 7.6 and viscosity value from 3 to 600 sSt. One variant of invention involves irrigative composition "Gidroelastic" for intraocular application comprises additionally medicinal agent and another variant involves irrigative composition with additional content of metal ions that are necessary for normal maintenance of metabolic processes in intraocular fluid. Invention provides reduction of irrigative trauma in surgery operations and, therefore, reduction of time for visual rehabilitation of patient after operation. EFFECT: enhanced effectiveness and valuable medicinal properties of composition. 3 cl, 3 ex
We report the case of a man in his late 30s who presented with a history of breathlessness and cough with haemoptysis. Complete blood counts revealed pancytopenia. High-resolution CT showed diffuse bilateral ground glass opacities. Sequential bronchoalveolar lavage confirmed alveolar haemorrhage. Bone marrow aspiration showed vacuoles in erythroid and myeloid precursor cells. The genome was sequenced, and the UBA1 gene revealed a c.121 A>G mutation (p.Met41Val), confirming vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome. The patient was managed with high-dose prednisolone pulse therapy. He improved with the complete resolution of the alveolar haemorrhage and an improvement in lung function and cytopenias.
BACKGROUND/AIM: Malignant melanoma is a tumor with a poor prognosis that can metastasize distally at an early stage. Terrein, a metabolite produced by Aspergillus terreus, suppresses the expression of angiogenin, an angiogenic factor. However, the pharmacological effects of natural terrein have not been elucidated, because only a small amount of terrein can be extracted from large fungal cultures. In this study, we investigated the antineoplastic effects of terrein on human malignant melanoma cells and its underlying mechanisms.
MATERIALS AND METHODS: Human malignant melanoma cell lines were cultured in the presence of terrein and analyzed. Angiogenin production was evaluated using ELISA. Ribosome biosynthesis was evaluated using silver staining of the nucleolar organizer region. Intracellular signaling pathways were analyzed using western blotting. Malignant melanoma cells were transplanted subcutaneously into the backs of nude mice. The tumors were removed at 5 weeks and analyzed histopathologically.
RESULTS: Terrein inhibited angiogenin expression, proliferation, migration, invasion, and ribosome biosynthesis in malignant melanoma cells. Terrein was shown to inhibit tumor growth and angiogenesis in animal models.
CONCLUSION: This study demonstrated that terrein has anti-tumor effects against malignant melanoma. Furthermore, chemically synthesized non-natural terrein can be mass-produced and serve as a novel potential anti-tumor drug candidate.
Patients with end stage renal disease (ESRD) are at high risk of developing upper tract urothelial carcinoma (UTUC). Due to high recurrence rate of UTUC in contralateral kidney and ureter, and high risk of complications related to surgery and anesthesia, whether it's necessary to remove both kineys and ureters at one time remains in debate. We utilized Taiwanese UTUC Registry Database to valuate the difference of oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving surgical resection. Patients with ESRD and UTUC were divided into three groups, unilateral UTUC, previous history of unilateral UTUC with metachronous contralateral UTUC, and concurrent bilatetral UTUC. Oncological outcomes, perioperative complications, and length of hospital stays were investiaged. We found that there is no diffence of oncological outcomes including overall survival, cancer specific survival, disease free survival and bladder recurrence free survival between these three groups. Complication rate and length of hospital stay are similar. Adverse oncological features such as advanced tumor stage, lymph node involvement, lymphovascular invasion, and positive surgical margin would negatively affect oncological outcomes.
Advances in airway management have led to development on videolaryngoscopy devices including the Glidescope® (Verathon Inc, Bothwell, USA), the AWD® (Pentax Corporation, Tokio, Japan) and most recently the Truview PCD (Truphatek International Ltd, Netanya, Israel). The use of videolaryngoscopy devices in adults have demonstrated some advantages including, minimal trauma on the airway and better view of the glottis.

The Glidescope is designed with a 60º angle and a camera on the inferior aspect just at the inflection point. The view is obtained anteriorly and the camera is located remote from the glottis providing a good visual field. The video image is displayed on a Liquid Crystal Display (LCD), with electronic recording available. Despite a good experience using Glidescope in adults, few studies have been published in pediatric patients. Kim et al. in a randomized study comparing the use of Glidescope with direct laryngoscopy in children, demonstrated better or equal laryngoscopic view with longer time for intubation using the Glidescope.
BACKGROUND: The transthoracic transdiaphragmatic approach (TTA) for hepatic tumors in laparoscopic liver resection (LLR) is not usually employed because the caudal approach via the abdominal cavity is the gold standard in LLRs. Here, we present a case of LLR via TTA for hepatocellular carcinoma (HCC) in a patient with severe obesity and a history of deceased donor liver transplantation (DDLT).
MATERIALS AND SURGICAL TECHNIQUE: The patient, a 64-year-old man with severe obesity and a history of DDLT, was referred to our hospital to undergo LLR for HCC located at the cranial side of segment IV. We decided to perform LLR via TTA because of concerns about the effect of severe adhesion, the difficulty of encircling the hepatoduodenal ligament, and the impact of severe obesity on the completion of LLR. Under general anesthesia with differential lung ventilation, we started to perform transthoracic ultrasonography to determine the diaphragmatic transection line. Then, we transected the diaphragm and revealed the tumor. We marked the parenchymal transection line with a 1-cm margin and then employed precoagulation of the hepatic parenchyma along the transection line. We performed parenchymal transection and clipped the responsible Glissonean pedicle at the bottom of the tumor. The diaphragm was closed using 3-0 nonabsorbable sutures with suture clips after the resected specimen was extracted.
DISCUSSION: We successfully performed LLR via TTA without hepatic inflow control. However, further studies are warranted to define the indications and recommendations for TTA in LLRs in the near future.
Introduction: Oral health and oral-health-associated quality-of-life (OHrQL) of residents in German nursing homes are poor. The investigators will develop an evidence-based catalogue of interventions applicable and sustainable ("Oral Health Tool Box"). Based on this, care-accompanying reinstruction and remotivation of nursing staff by dental assistants (DA) will be provided. The investigators hypothesize such complex intervention to significantly improve OHrQL, and daily oral hygiene/care behaviour and its cost-effectiveness.

Methods and analysis: Based on the findings of a rapid systematic review, possible intervention components will be systematized and assessed for their effectiveness. Mixed methods will be used to identify barriers and enablers of oral hygiene and care in German long-term residential care (LRC), and these will be linked with the intervention components using the Theoretical Domains Framework and the Behavior Change Wheel, the result being an "Oral Health Tool Box". A two-arm cluster, randomized-controlled-trial (ratio of 1:1 via block randomization) will be performed in nursing homes in Rhineland-Palatinate, Germany, including residents with moderate to severe care dependency. Each nursing home represents a cluster. Based on a feasibility study, considering clustering and possible attrition, the investigators aim at recruiting 618 residents of 18 cluster. In the intervention group, dentists will identify the specific problems of each resident, and assign one or more intervention components from the box. During follow-up, nursing staff will be reinstructed and remotivated by dental assistants in how to deliver the intervention components in individual intervals. In the control group residents will receive care as usual. The primary outcome, OHrQL, will be measured using the German version of the General Oral Health Assessment Index (GOHAI). Secondary outcomes include pain condition, general health-related quality-of-life, caries increment, oral/prothetic hygiene and gingival status, incidence of dental emergencies and hospitalizations, and cost-utility/effectiveness. The endpoints will be measured at baseline and after 12 months. For the primary outcome, a mixed-linear model will be used within an intention-to-treat analysis. A process evaluation using mixed methods will be conducted alongside the trial.

Due to the pandemic, the number of cases could not be reached despite outstanding commitment in recruitment. An application was made to the funding agency to adapt the project plan.
The study will enroll 200 adults ages 18-60 admitted to the hospital with severe open or closed fractures of the proximal tibia or tibial shaft at risk for ACS. Participants will be randomized to either treatment with tissue ultrafiltration (TUF) catheters (n=100) or to a control group (n=100). All patients will receive continuous pressure monitoring of the anterior compartment of their leg. Both groups will receive comprehensive clinical evaluation and will be treated according to the standard-of-care regarding management of their underlying injury and diagnosis of ACS as practiced by their treating surgeon. In addition, patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle. All patients will be followed at 6 months following initial hospital discharge. This visit will include a clinical evaluation of complications, hospital admission and emergency room visits, wound and fracture healing, infection, muscle sensory and function exam and patient-reported outcome.

The study approach hypothesizes that the expert panel consensus likelihood of ACS, defined as the median of the ratings of the individual panel members who evaluated each patient, the incidence of fasciotomy, and intramuscular pressure (IMP) will be lower in the TUF cohort compared to control. In addition, patients in the TUF cohort will demonstrate superior functional outcome and muscle strength at 6 months following injury compared to those in the control cohort, levels of specific biomarkers as measured in the interstitial fluid will be worse in patients with ACS compared to patients without ACS in the treatment group, and there will be a threshold for each biomarker which is predictive of ACS (biomarkers will be collected from 10 patients enrolled at Hennepin Healthcare only).
The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
Patients who are undergoing endovascular intervention will be enrolled into the study. Consent will be obtained for the procedure and for the use of their prospectively collected clinical data. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a "radial first" approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr). If the artery does not meet the size criteria, only a 6Fr sheath will be used, and the data recorded during the procedure will not be utilized for analysis in this study. The preoperative and postoperative care will be the same for all the patients. No tests will be done outside of standard of care.
Participants will receive a single dose of apalutamide 240 milligram (mg) (4\*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A \[reference\]) followed by a single dose of apalutamide 240 mg (4\*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B \[test\]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.